
FSTX
Healthcare · Biotechnology · $156.5M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · +29.1% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 10, 2022 | After the close | -0.79 | -0.84 | -6.3% |
| Aug 11, 2022 | Before the open | -0.58 | -0.88 | -51.7% |
| May 10, 2022 | Before the open | -0.67 | -0.57 | +14.9% |
| Mar 14, 2022 | Before the open | -0.11 | 0.48 | +536.4% |
| Nov 10, 2021 | Before the open | -0.58 | -0.52 | +10.3% |
| Aug 12, 2021 | Before the open | -0.74 | -0.92 | -24.3% |
| May 17, 2021 | Before the open | -1.16 | -1.08 | +6.9% |
| Mar 29, 2021 | Before the open | -0.64 | -2.10 | -228.1% |
| Nov 3, 2020 | After the close | -1.00 | -1.24 | -24.0% |
| Aug 10, 2020 | After the close | -1.44 | -1.52 | -5.6% |
| May 7, 2020 | After the close | -0.80 | -1.96 | -145.0% |
| Feb 14, 2020 | Before the open | -2.68 | -1.80 | +32.8% |
| Nov 7, 2019 | After the close | -2.43 |
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of…
| -1.68 |
| +30.9% |
| Jul 31, 2019 | After the close | -2.22 | -1.12 | +49.5% |
| Apr 29, 2019 | Before the open | -2.09 | -1.28 | +38.8% |
| Mar 11, 2019 | Before the open | -2.26 | -1.36 | +39.8% |
| Oct 25, 2018 | After the close | -0.61 | -0.59 | +3.3% |
| Aug 1, 2018 | After the close | -0.53 | -0.29 | +45.3% |
| Apr 27, 2018 | Before the open | -0.57 | -0.37 | +35.1% |
| Feb 20, 2018 | After the close | -0.54 | -0.11 | +79.6% |